日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting

针对LP.8.1的COVID-19 mRNA疫苗可持久增强中和抗体并减轻祖先免疫印记

Mellis, Ian A; Wu, Madeline; Hong, Hsiang; Bowen, Anthony; Daniel, Kristin; Gherasim, Carmen; Pierce, Virginia M; Yin, Michael T; Gordon, Aubree; Guo, Yicheng; Ho, David D

ACE-2-like Enzymatic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies

抗SARS-CoV-2刺突蛋白单克隆抗体中的ACE-2样酶活性

Song, Yufeng; Mehl, Frances; No, Tom; Livingston, Lauren; Quintero Barbosa, Juan Sebastian; Hayashi, Jun; Serrero, Ginette; Bortz, Pamela Schoppee; Wilson, Jeffrey; Crowe, James E; Ho, David D; Yin, Michael T; Tan, Joshua; Zeichner, Steven L

Doxy-PEP in the Dominican Republic: Investigating Healthcare Provider Knowledge, Attitudes, and Practices in a Caribbean Clinical Setting

多西环素-暴露后预防在多米尼加共和国的应用:调查加勒比临床环境中医疗服务提供者的知识、态度和实践

Longhi, Daniella; Myrus, Elizabeth; Baez Caraballo, Pamela; Reyes, Feldin; D'Avanzo, Paul A; Yin, Michael T; Zucker, Jason

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

基于KP.2的单价mRNA疫苗可显著增强对SARS-CoV-2的抗体反应。

Wang, Qian; Mellis, Ian A; Wu, Madeline; Bowen, Anthony; Gherasim, Carmen; Valdez, Riccardo; Shah, Jayesh G; Purpura, Lawrence J; Yin, Michael T; Gordon, Aubree; Guo, Yicheng; Ho, David D

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

SARS-CoV-2 LP.8.1.1、NB.1.8.1、XFG 及相关亚型的抗体逃避和受体结合

Mellis, Ian A; Wu, Madeline; Hong, Hsiang; Tzang, Chih-Chen; Bowen, Anthony; Wang, Qian; Gherasim, Carmen; Pierce, Virginia M; Shah, Jayesh G; Purpura, Lawrence J; Yin, Michael T; Gordon, Aubree; Guo, Yicheng; Ho, David D

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.

SARS-CoV-2 亚型 KP.3.1.1 和 XEC 的抗体逃避能力

Wang Qian, Guo Yicheng, Mellis Ian A, Wu Madeline, Mohri Hiroshi, Gherasim Carmen, Valdez Riccardo, Purpura Lawrence J, Yin Michael T, Gordon Aubree, Ho David D

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

针对危重患者多粘菌素B的群体药代动力学/毒效学模型,用于识别肾毒性风险

Hanafin, Patrick O; Mahadevan, Ramya; Rao, Gauri G; Zavascki, Alexandre P; Sandri, Ana Maria; Kwa, Andrea; Scheetz, Marc H; Kubin, Christine J; Shah, Jayesh; Cherng, Benjamin P Z; Yin, Michael T; Wang, Jiping; Wang, Lu; Calfee, David P; Bolon, Maureen; Purcell, Anthony W; Nation, Roger L; Pogue, Jason M; Li, Jian; Kaye, Keith S

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients.

首创的 Bcl-2/Bcl-xL 双重降解剂可逆转 HIV 潜伏期并最大限度地减少患者体外病毒库

Chang Lin-Chun, Yin Michael T, Laird Gregory M, Ritter Kristen D, Shah Jayesh G, Debnath Asim K

ACE-2-like enzymatic activity in COVID-19 convalescents with persistent pulmonary symptoms associated with immunoglobulin.

COVID-19 康复期患者持续存在肺部症状,且伴有免疫球蛋白相关 ACE-2 样酶活性

Song Yufeng, Mehl Frances, Muehling Lyndsey M, Canderan Glenda, Enfield Kyle, Sun Jie, Yin Michael T, Ratcliffe Sarah J, Wilson Jeffrey M, Kadl Alexandra, Woodfolk Judith A, Zeichner Steven L

Association Between Inpatient Medication Treatment for Opioid Use Disorder and Reduced One-Year All-Cause Mortality in Patients With Invasive Bacterial Infections

住院药物治疗阿片类药物使用障碍与侵袭性细菌感染患者一年全因死亡率降低之间的关联

Blair, Nicholas J; Kopp, Adam; Kubin, Christine; Cotton, Jesse; Yin, Michael T; Scherer, Matthew